Literature DB >> 19381839

Workshop report and follow-up--AAPS Workshop on current topics in GLP bioanalysis: Assay reproducibility for incurred samples--implications of Crystal City recommendations.

Douglas M Fast1, Marian Kelley, C T Viswanathan, Jacqueline O'Shaughnessy, S Peter King, Ajai Chaudhary, Russell Weiner, Anthony J DeStefano, Daniel Tang.   

Abstract

The Conference Report of the 3rd AAPS/FDA Bioanalytical Workshop (Crystal City III) endorsed the concept that assay methods supporting bioanalytical data in submissions must demonstrate assay reproducibility by using incurred samples. The present Workshop was convened to provide a forum for discussion and consensus building about incurred sample assay reproducibility for both nonclinical and clinical studies. Information about current regulatory perspectives on incurred sample reanalysis (ISR) was presented, implications of ISR for both large and small molecules were discussed, and the steering committee put forth recommendations for performing ISR. These recommendations from the Workshop, along with the subsequent evolution of approaches leading to a robust ISR program, may be used by scientists performing bioanalytical assays for regulated studies to provide additional confirmation of assay reproducibility for incurred samples.

Mesh:

Substances:

Year:  2009        PMID: 19381839      PMCID: PMC2691460          DOI: 10.1208/s12248-009-9100-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  5 in total

1.  Impact of differential recovery in bioanalysis: the example of bortezomib in whole blood.

Authors:  Adam H Brockman; Panos Hatsis; Martin Paton; Jing-Tao Wu
Journal:  Anal Chem       Date:  2007-02-15       Impact factor: 6.986

2.  Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays.

Authors:  C T Viswanathan; Surendra Bansal; Brian Booth; Anthony J DeStefano; Mark J Rose; Jeffrey Sailstad; Vinod P Shah; Jerome P Skelly; Patrick G Swann; Russell Weiner
Journal:  Pharm Res       Date:  2007-04-26       Impact factor: 4.200

Review 3.  Confirmatory reanalysis of incurred bioanalytical samples.

Authors:  Mario L Rocci; Viswanath Devanarayan; David B Haughey; Paula Jardieu
Journal:  AAPS J       Date:  2007-10-05       Impact factor: 4.009

4.  A strategy for a post-method-validation use of incurred biological samples for establishing the acceptability of a liquid chromatography/tandem mass-spectrometric method for quantitation of drugs in biological samples.

Authors:  Mohammed Jemal; Zheng Ouyang; Mark L Powell
Journal:  Rapid Commun Mass Spectrom       Date:  2002       Impact factor: 2.419

5.  Determination of rifalazil in dog plasma by liquid-liquid extraction and LC-MS/MS: quality assessment by incurred sample analysis.

Authors:  Marita Larsson; Feng Han
Journal:  J Pharm Biomed Anal       Date:  2007-09-12       Impact factor: 3.935

  5 in total
  33 in total

Review 1.  Assay formats: Recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team.

Authors:  Sherri Dudal; Daniel Baltrukonis; Rebecca Crisino; M Jaya Goyal; Alison Joyce; Karolina Osterlund; John Smeraglia; Yoshitaka Taniguchi; Jihong Yang
Journal:  AAPS J       Date:  2013-12-17       Impact factor: 4.009

2.  Statistical considerations for assessment of bioanalytical incurred sample reproducibility.

Authors:  David Hoffman
Journal:  AAPS J       Date:  2009-08-08       Impact factor: 4.009

3.  An approach to the validation of flow cytometry methods.

Authors:  Jo Cunliffe; Nicola Derbyshire; Sue Keeler; Ruth Coldwell
Journal:  Pharm Res       Date:  2009-10-14       Impact factor: 4.200

4.  Assessment of incurred sample reanalysis for macromolecules to evaluate bioanalytical method robustness: effects from imprecision.

Authors:  Theingi M Thway; Michael Eschenberg; Dominador Calamba; Chris Macaraeg; Mark Ma; Binodh DeSilva
Journal:  AAPS J       Date:  2011-04-03       Impact factor: 4.009

5.  Tiered approaches to chromatographic bioanalytical method performance evaluation: recommendation for best practices and harmonization from the Global Bioanalysis Consortium harmonization team.

Authors:  S Lowes; R Hucker; M Jemal; J C Marini; V M Rezende; R Shoup; P Singhal; P Timmerman; T Yoneyama; N Weng; D Zimmer
Journal:  AAPS J       Date:  2014-10-23       Impact factor: 4.009

6.  Analysis of imprecision in incurred sample reanalysis for small molecules.

Authors:  Sriram Subramaniam; Devvrat Patel; Barbara M Davit; Dale P Conner
Journal:  AAPS J       Date:  2014-10-30       Impact factor: 4.009

7.  Workshop report: Crystal City V--quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidance.

Authors:  Brian Booth; Mark E Arnold; Binodh DeSilva; Lakshmi Amaravadi; Sherri Dudal; Eric Fluhler; Boris Gorovits; Sam H Haidar; John Kadavil; Steve Lowes; Robert Nicholson; Marie Rock; Michael Skelly; Lauren Stevenson; Sriram Subramaniam; Russell Weiner; Eric Woolf
Journal:  AAPS J       Date:  2014-12-31       Impact factor: 4.009

Review 8.  Repeat analysis and incurred sample reanalysis: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team.

Authors:  Eric Fluhler; Faye Vazvaei; Puran Singhal; Petra Vinck; Wenkui Li; Jignesh Bhatt; Theo de Boer; Ajai Chaudhary; Masahiro Tangiuchi; Vinicius Rezende; Dafang Zhong
Journal:  AAPS J       Date:  2014-08-19       Impact factor: 4.009

9.  Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC/MS/MS.

Authors:  Lee C Winchester; Anthony T Podany; Joshua S Baldwin; Brian L Robbins; Courtney V Fletcher
Journal:  J Pharm Biomed Anal       Date:  2014-11-18       Impact factor: 3.935

Review 10.  Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.

Authors:  J Cummings; F Raynaud; L Jones; R Sugar; C Dive
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.